The trusted partner for RNA success

Eclipsebio supports RNA discovery and development through integrated design, analytics, and characterization. From therapeutics and oligonucleotides to small molecules and basic research, we deliver the insights needed to advance programs with confidence.

Animation image

Comprehensive RNA therapy support

Eclipsebio supports RNA therapeutic development from early design through prototyping, characterization, and scale-up. Our integrated solutions combine AI-powered sequence design, rapid in-house RNA prototyping, and sequencing-first analytics powered by eMERGE to deliver actionable insight into the critical quality attributes that drive therapeutic success. Engage us end-to-end across the full development lifecycle or plug in where needed to accelerate decisions, reduce risk, and advance programs toward the clinic.

Our other RNA solutions:

Beyond RNA therapeutics, we also offer integrative solutions that support RNA-targeting modalities, AI-driven discovery, and fundamental RNA research

AI Training Data

To support accurate AI model training for drug discovery, we provide high-quality, reproducible datasets through our eVERSE platform.

Small Oligonucleotides

With our holistic approach to small oligonucleotide design and validation, we provide RNAi and ASO developers with the data needed for clinical success. Learn how we perform multiomic profiling of targets and robustly measure off-target effects.

Small Molecules

Our integrative portfolio of assays reveals disease-specific, accessible regions of target RNAs and provides deep profiling of on-target and off-target therapeutic effects.

Basic Research

For our academic partners, we provide a la carte and integrative solutions that deliver a comprehensive view of RNA biology, from secondary structure to protein regulation.

What Our Partners

and Collaborators Say

Card icon

"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures… to help improve the design of our RNAs and rationalize our internal findings."

Card icon

"Eclipsebio was the only company that could perform the robust siRNA off-target binding analysis we needed. Their experimental results provided important additional insights into our own internal findings. We look forward to continuing to work with Eclipsebio in the future."

Card icon

"Eclipsebio has been an invaluable partner to Deep Genomics. They've helped us generate massive miRNA-related datasets for training AI models, and have designed and conducted bespoke assays to illuminate the mechanism underlying some of our lead therapeutic compounds."

Card icon

"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."

New at Eclipsebio

Expanding our RNA platform

Eclipsebio has acquired Terrain Bio, bringing RNA design and prototyping together with sequencing-powered analytics to support RNA therapeutics from design through validation.

Discover AI success

Artificial intelligence and machine learning are revolutionizing drug discovery. eVERSE is our portfolio of next-generation sequencing data, tailored for AI model training. Discover how eVERSE provides the data needed for success here.

Learn with our newest blog

Discover how closed-loop RNA development pairs design and sequencing to accelerate better therapeutics.

Find out where we will be next

Our team of RNA experts is presenting at conferences and webinars to highlight the power of RNA solutions for therapeutic success. Discover where we will be discussing our platform and partnership opportunities.